Cepheid Nabs First FDA Authorization For Rapid-Response COVID-19 Test
Point-of-care test can give results in 45 minutes
Executive Summary
A rapid-response test from Danaher business unit Cepheid will be the first quick COVID-19 diagnostic to reach the US market, the US FDA announced on 21 March.